We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

322 hedge funds and large institutions have $1.58B invested in Recursion Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 131 increasing their positions, 76 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more repeat investments, than reductions

Existing positions increased: 131 | Existing positions reduced: 76

70% more call options, than puts

Call options by funds: $52.4M | Put options by funds: $30.7M

1% more capital invested

Capital invested by funds: $1.57B → $1.58B (+$12.1M)

1.76% less ownership

Funds ownership: 77.63% → 75.87% (-1.8%)

3% less funds holding

Funds holding: 332 → 322 (-10)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

12% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 51

Holders
322
Holders Change
-10
Holders Change %
-3.01%
% of All Funds
4.23%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.11%
New
45
Increased
131
Reduced
76
Closed
51
Calls
$52.4M
Puts
$30.7M
Net Calls
+$21.7M
Net Calls Change
+$7.03M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$37.2M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19.5M
3
BlackRock
BlackRock
New York
+$17.7M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$11.5M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.7M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.4M
2
NHAS
Novo Holdings A/S
Denmark
-$9.11M
3
UBS Group
UBS Group
Switzerland
-$4.6M
4
VAS
Vestmark Advisory Solutions
Massachusetts
-$3.77M
5
Millennium Management
Millennium Management
New York
-$3.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
26
First Trust Advisors
Illinois
$8.77M -$436K -83,085 -4%
IEFM
27
IQ EQ Fund Management
Ireland
$8.66M +$4.54M +863,910 +95%
BPCE
28
Bank Pictet & Cie (Europe)
Germany
$7.95M +$8.56M +1,630,000 New
Barclays
29
Barclays
United Kingdom
$7.57M +$2.02M +385,537 +33%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$6.68M +$1.51M +288,454 +27%
Citadel Advisors
31
Citadel Advisors
Florida
$6.58M +$179K +34,132 +3%
N
32
Nuveen
North Carolina
$6.23M +$267K +50,778 +4%
Goldman Sachs
33
Goldman Sachs
New York
$6.16M +$685K +130,402 +12%
Bank of America
34
Bank of America
North Carolina
$5.97M -$814K -154,938 -11%
CFM
35
Comprehensive Financial Management
California
$4.6M – – –
Two Sigma Advisers
36
Two Sigma Advisers
New York
$3.98M +$4.28M +815,445 New
Wells Fargo
37
Wells Fargo
California
$3.91M +$3.07M +584,332 +269%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$3.66M +$2.07M +394,022 +111%
Capital Fund Management (CFM)
39
Capital Fund Management (CFM)
France
$3.54M +$28.9K +5,498 +0.8%
Jane Street
40
Jane Street
New York
$3.52M +$3.79M +721,554 New
VAS
41
Vestmark Advisory Solutions
Massachusetts
$3.03M -$3.77M -718,080 -54%
Swiss National Bank
42
Swiss National Bank
Switzerland
$3.03M +$286K +54,400 +10%
PBPIA
43
Pivotal bioVenture Partners Investment Advisor
California
$2.91M – – –
NFGH
44
Nan Fung Group Holdings
Hong Kong
$2.91M -$364K -69,323 -10%
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$2.74M +$2.95M +562,448 New
JF
46
Jump Financial
Illinois
$2.71M -$3.13M -596,123 -52%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$2.54M +$18.5K +3,530 +0.7%
Lazard Asset Management
48
Lazard Asset Management
New York
$2.42M +$477K +90,800 +22%
Stifel Financial
49
Stifel Financial
Missouri
$2.16M +$980K +186,703 +73%
JP Morgan Chase
50
JP Morgan Chase
New York
$2.05M +$106K +20,115 +5%
1
2
3 4 5

RXRX Hedge Fund Activity: Q3 2025 in Review

322 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2025, worth a combined $1.58B — up 0.77% from $1.57B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of RXRX and 45 opened new positions — a net loss of 6 holders — while 76 trimmed existing stakes and 131 added.

The largest buyer was State Street, adding an estimated $37.2M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.

  • 322 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2025, down from 332 in Q2 2025.
  • Funds reported $1.58B of Recursion Pharmaceuticals stock for Q3 2025, up 0.77% quarter-over-quarter.
  • 45 funds opened new Recursion Pharmaceuticals positions in Q3 2025 and 51 closed out, a net change of -6 holders.
  • The largest Recursion Pharmaceuticals buyer in Q3 2025 was State Street, an estimated $37.2M added.
  • The largest Recursion Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2025.